Adaptive Biotechnologies (ADPT) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue reached $46.4 million, up 22% year-over-year, driven by strong MRD segment growth and regulatory milestone revenue.

• MRD revenue grew 52% year-over-year to $37.5 million, with clinical and pharma segments benefiting from regulatory milestones and increased adoption, especially in multiple myeloma.

• Net loss narrowed to $32.1 million from $50.3 million in Q3 2023, reflecting improved operating leverage and cost controls.

• Operating expenses decreased 11% year-over-year to $79.1 million, with significant cost-saving initiatives and a 38% reduction in year-to-date cash burn.

• Cash, cash equivalents, and marketable securities totaled approximately $267 million as of September 30, 2024, supporting ongoing operations and strategic initiatives.

Financial highlights

• Q3 2024 total revenue was $46.4 million, up 22% year-over-year; MRD revenue was $37.5 million, up 52%; Immune Medicine revenue was $9.0 million, down 32%.

• clonoSEQ test volume increased 30% year-over-year to 19,600 tests; U.S. ASP grew 3% despite a $1.8 million reserve charge.

• Gross margin improved to 64%, with sequencing gross margin up 13 percentage points year-over-year; cost of revenue as a percentage of revenue decreased to 36% from 51%.

• Adjusted EBITDA loss narrowed to $14.3 million from $29.8 million a year ago.

• Net loss per share improved to $(0.22) from $(0.35) in Q3 2023.

Outlook and guidance

• Full-year MRD revenue guidance raised to $143–$145 million, reflecting better-than-expected Q3 performance.

• Full-year operating expenses (excluding one-time items) expected at $335–$340 million, down from prior guidance.

• Annual cash burn forecast reduced to $105 million, a 31% reduction from 2023.

• Management expects long-term MRD and Immune Medicine revenue growth as clinical testing volume and collaborations advance.

• Existing cash and marketable securities are expected to fund operations and capital needs for at least the next 12 months.